title: [Molecular targeted therapy for malignant brain tumors].
authors.affiliation: Department of Surgery, Section of Molecular Therapeutics, Duke University Medical Center.
authors.forename: Tatsunori
authors.initials: T
authors.lastname: Okamura
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kurisu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D016503:Drug Delivery Systems; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D005910:Glioma / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D047908:Intracellular Signaling Peptides and Proteins / Q000494:pharmacology / Q000627:therapeutic use; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000235:genetics; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases; D003986:Dibenzocycloheptenes
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D066246:ErbB Receptors; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D000068877:Imatinib Mesylate; D047908:Intracellular Signaling Peptides and Proteins; D020928:Mitogen-Activated Protein Kinases; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010879:Piperazines; D010880:Piperidines; D011494:Protein Kinases; D011505:Protein-Tyrosine Kinases; D011725:Pyridines; D011743:Pyrimidines; D011799:Quinazolines; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C015482:protein kinase modulator; C546842:MTOR protein, human; C115354:lonafarnib; D003986:Dibenzocycloheptenes